drugset / Trial / NCT00050960

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

NCT00050960

Phase 3 Completed 612 enrolled Eisai Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

Timeline

Start
2002-05
Primary completion
2004-07
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexarotene Small molecule 400 mg/m2
Background Carboplatin Small molecule Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous